Altered tumor uptake and cycledependent effects of [¹⁷⁷Lu]LuPSMA617 combined with EBRT and ADT in treatmentnaïve patients: a population pharmacokinetic analysis (EANM 2026) - Sep 29, 2026 - Abstract #EP-1225; P1 | "This analysis showed clinically relevant differences in tumor uptake of [177Lu]Lu-PSMA-617 in an early-stage multimodal vs metastatic monotherapy setting. Variability was largely explained by cycle and tumor volume effects. Indications of nonlinear tumor uptake support considering saturation effects in future studies."
Clinical • PK/PD data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
|
|
D. van Asten 1, 2; B. J. de Wit-van der Veen 2; W. V. Vogel 2; A. Huitema 1, 3, 4; H. Huisman-Siebinga 1, 2
|